News2021-05-28T14:12:08-05:00
1215, 2020

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient has been dosed in its Phase 2 clinical trial evaluating ecopipam, the company’s investigational medicine, for the treatment of childhood-onset fluency disorder, or “stuttering.” The [...]

099, 2020

Jon DeVries Named Qlarity Imaging Chief Executive Officer

Chicago, September 9, 2020 – Life science innovator Paragon Biosciences announced the appointment of Jon T. DeVries as the new chief executive officer of its portfolio company, Qlarity Imaging, a leading artificial intelligence (AI) diagnostics company. A proven leader with in-depth expertise in developing and commercializing medical imaging and AI solutions, Mr. DeVries will be responsible for executing [...]

091, 2020

Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone

– Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – Chicago – September 1, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced today that its Phase 2b [...]

0821, 2020

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

PLYMOUTH MEETING, PA and CHICAGO, IL, August 21, 2020 — Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced it has closed its upsized initial public offering of 6,151,162 shares of common stock, including 802,325 [...]

0819, 2020

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering

PLYMOUTH MEETING, PA and CHICAGO, IL, August 18, 2020 — Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today the pricing of its upsized initial public offering of 5,348,837 shares of common stock at a price [...]

0812, 2020

Paragon Biosciences Appoints Kerensa Jimenez as Paragon Health Capital Chief Executive Officer

Chicago, August 12, 2020 – With strong momentum in its growing portfolio of life science companies, Paragon Biosciences announced the appointment of Kerensa Jimenez as the new chief executive officer of its capital markets group, Paragon Health Capital (PHC), a registered broker-dealer. With deep experience and a proven track record, Ms. Jimenez will spearhead all financings, [...]

Archives
Go to Top